COMP <GO>
IBO vs ACET // EV/EBITDA & P/E VALUATION
Impact BioMedical Inc. (NYSE) VS. Adicet Bio Inc. (NASDAQ) • 15-METRIC TALLY: IBO 2
— ACET 2
■ METRIC PARITY
LAST: $3.87 (-3.00%) • MKT CAP: $33.1M
valuation
—
LAST: $3.58 (-6.04%) • MKT CAP: $33.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IBO VS. ACET)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IBO | ACET | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | -30.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.50% | -35.00% | +7.50 | IBO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.72% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.88 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | ACET | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.5 | 22.7 | +21.80 | IBO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $33.1M | $33.5M | -$450.1K | ACET | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IBO REV | ACET REV | IBO GROSS % | ACET GROSS % | IBO FCF | ACET FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $32.0K | $0 | -50.0% | — | -$1.9M | -$97.0M |
| FY 2024 | $0 | $0 | — | — | -$2.9M | -$93.5M |
| FY 2023 | $0 | $0 | — | — | -$2.9M | -$93.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IBO // BETA —
ACET // BETA —